Browse result page of CancerPDF Database
Please click on CancerPDF_ID for detailed information about peptide.
CancerPDF_ID | Peptide seq | Protein Name | Fluid | Mass/Z | Profiling Technique | Cancer Type | Expression Regulation | PUBMED ID |
---|---|---|---|---|---|---|---|---|
CancerPDF_ID9450 | RPPGFSPF | Des-Arg9 Bradykinin | Plasma | 904.46 | MALDI-TOF | Colorectal cancer | Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. | 26379225 |
CancerPDF_ID9451 | NA | NA | Plasma | 991.67 | MALDI-TOF | Colorectal cancer | NA | 26379225 |
CancerPDF_ID9452 | NA | NA | Plasma | 1015.66 | MALDI-TOF | Colorectal cancer | NA | 26379225 |
CancerPDF_ID9453 | SHALQLNNR | Complement C4-A/Complement C4-B | Plasma | 1052.56 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
CancerPDF_ID9454 | RPPGFSPFR | Bradykinin | Plasma | 1060.57 | MALDI-TOF | Colorectal cancer | Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. | 26379225 |
CancerPDF_ID9455 | RPPGFSPFR | oxidated Bradykinin | Plasma | 1076.56 | MALDI-TOF | Colorectal cancer | Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. | 26379225 |
CancerPDF_ID9456 | HWESASLLR | Complement C3 | Plasma | 1098.57 | MALDI-TOF | Colorectal cancer | "Lower intensity in control, adenoma, early,late CRC and much more lower in liver metastasis group." | 26379225 |
CancerPDF_ID9457 | THRIHWESA | Complement C3 | Plasma | 1136.57 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9458 | LQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1154.68 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
CancerPDF_ID9459 | IHWESASLLR | Complement C3 | Plasma | 1211.65 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
CancerPDF_ID9460 | ALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1225.72 | MALDI-TOF | Colorectal cancer | "Intensity was similar to controls, controversially, in adenoma and CRC groups was highest. " | 26379225 |
CancerPDF_ID9461 | ITHRIHWESA | Complement C3 | Plasma | 1249.65 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9462 | MEPLGRQLTSGP | Alpha-2-antiplasmin | Plasma | 1285.66 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
CancerPDF_ID9463 | RHDWGHEKQR | Kininogen-1 | Plasma | 1348.63 | MALDI-TOF | Colorectal cancer | Not significant in annova test | 26379225 |
CancerPDF_ID9464 | RIHWESASLLR | Complement C3 | Plasma | 1367.77 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
CancerPDF_ID9465 | KITHRIHWESA | Complement C3 | Plasma | 1377.72 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9466 | GLEEELQFSLGSK | Complement C4-A/Complement C4-B | Plasma | 1436.72 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
CancerPDF_ID9467 | SHALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1449.77 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis group than adenoma and CRC groups | 26379225 |
CancerPDF_ID9468 | SKITHRIHWESA | Complement C3 | Plasma | 1464.77 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9469 | NGFKSHALQLNNR | Complement C4-A/Complement C4-B | Plasma | 1499.79 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis group than adenoma and CRC groups | 26379225 |
CancerPDF_ID9470 | RPHFFFPKSRIV | Clusterin | Plasma | 1530.86 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
CancerPDF_ID9471 | SSKITHRIHWESA | Complement C3 | Plasma | 1551.82 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9472 | THRIHWESASLLR | Complement C3 | Plasma | 1605.87 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
CancerPDF_ID9473 | GPPDVPDHAAYHPFR | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 1675.8 | MALDI-TOF | Colorectal cancer | Lower intensity in liver metastasis than control groups and an opposite trend in adenoma and CRC group. | 26379225 |
CancerPDF_ID9474 | ITHRIHWESASLLR | Complement C3 | Plasma | 1718.95 | MALDI-TOF | Colorectal cancer | Similar intensity into the case groups. | 26379225 |
CancerPDF_ID9475 | SKITHRIHWESASLL | Complement C3 | Plasma | 1777.98 | MALDI-TOF | Colorectal cancer | Higher than adenoma and CRC groups | 26379225 |
CancerPDF_ID9476 | GFKSHALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1782 | MALDI-TOF | Colorectal cancer | Higher intensity in liver metastasis than adenoma and CRC groups. | 26379225 |
CancerPDF_ID9477 | KITHRIHWESASLLR | Complement C3 | Plasma | 1847.04 | MALDI-TOF | Colorectal cancer | "Low expression in control, adenoma, early,late CRC and much more lower in liver metastasis group." | 26379225 |
CancerPDF_ID9478 | SSKITHRIHWESASLL | Complement C3 | Plasma | 1865 | MALDI-TOF | Colorectal cancer | Similar intensity into the case groups. | 26379225 |
CancerPDF_ID9479 | GLEEELQFSLGSKINVK | Complement C4-A/Complement C4-B | Plasma | 1891.02 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
CancerPDF_ID9480 | NGFKSHALQLNNRQIR | Complement C4-A/Complement C4-B | Plasma | 1896.03 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
CancerPDF_ID9481 | NGFKSHALQLNNRQIR(NH4) | Complement C4-A/Complement C4-B | Plasma | 1913.01 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
CancerPDF_ID9482 | SKITHRIHWESASLLR | Complement C3 | Plasma | 1934.07 | MALDI-TOF | Colorectal cancer | "Low expression in control, adenoma, early,late CRC and much more lower in liver metastasis group." | 26379225 |
CancerPDF_ID9483 | SSKITHRIHWESASLLR | Complement C3 | Plasma | 2021.1 | MALDI-TOF | Colorectal cancer | "Low expression in control, adenoma, early,late CRC and much more lower in liver metastasis group." | 26379225 |
CancerPDF_ID9484 | SSKITHRIHWESASLLR | Complement C3 | Plasma | 2037.09 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9485 | SSKITHRIHWE(Na)SASLLR | Complement C3 | Plasma | 2043.1 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9486 | SSKITHRIHWE(K)SASLLR | Complement C3 | Plasma | 2059 | MALDI-TOF | Colorectal cancer | "Expression levels similar for liver metastasis and controls, but for adenoma and CRC groups was higher than controls." | 26379225 |
CancerPDF_ID9487 | QLGLPGPPDVPDHAAYHPFR | Inter-alpha-trypsin inhibitor heavy chain H4 | Plasma | 2167.08 | MALDI-TOF | Colorectal cancer | Higher intensity in CRC groups vs controls. | 26379225 |
CancerPDF_ID9488 | QGVNDNEEGFFSARGHRPLD | Fibrinogen beta chain | Plasma | 2228.03 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
CancerPDF_ID9489 | KREEAPSLRPAPPPISGGGYR | Fibrinogen beta chain | Plasma | 2235.21 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
CancerPDF_ID9490 | QGVNDNEEGFFSARGHRPLDK | Fibrinogen beta chain | Plasma | 2356.13 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
CancerPDF_ID9491 | KHNLGHGHKHERDQGHGHQR | Kininogen-1 | Plasma | 2365.22 | MALDI-TOF | Colorectal cancer | "Low expression in control and liver metastatis group as comapred to adenoma, early,late CRC group." | 26379225 |
CancerPDF_ID9492 | GLEEELQFSLGSKINVKVGGNSK | Complement C4-A/Complement C4-B | Plasma | 2433.3 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |
CancerPDF_ID9493 | SSSYSKQFTSSTSYNRGDSTFESK | Fibrinogen alpha chain | Plasma | 2681.21 | MALDI-TOF | Colorectal cancer | "Similar median ion intensity between controls and liver metastasis, and higher median ion intensity for adenoma and CRC groups." | 26379225 |